168 related articles for article (PubMed ID: 19210223)
41. Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations.
Nindl I; Zumbach K; Pawlita M; Teller K; Schneider A; Dürst M
J Infect Dis; 2000 May; 181(5):1764-7. PubMed ID: 10783118
[TBL] [Abstract][Full Text] [Related]
42. Comparison of cervical and blood T-cell responses to human papillomavirus-16 in women with human papillomavirus-associated cervical intraepithelial neoplasia.
Passmore JA; Milner M; Denny L; Sampson C; Marais DJ; Allan B; Gumbi PP; Hitzeroth II; Rybicki EP; Williamson AL
Immunology; 2006 Dec; 119(4):507-14. PubMed ID: 17026720
[TBL] [Abstract][Full Text] [Related]
43. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D
Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128
[TBL] [Abstract][Full Text] [Related]
44. Antibody detection against HPV16 E7 & GP96 fragments as biomarkers in cervical cancer patients.
Bolhassani A; Zahedifard F; Taslimi Y; Taghikhani M; Nahavandian B; Rafati S
Indian J Med Res; 2009 Nov; 130(5):533-41. PubMed ID: 20090101
[TBL] [Abstract][Full Text] [Related]
45. HPV-16-related proteins as the serologic markers in cervical neoplasia.
Park JS; Park DC; Kim CJ; Ahn HK; Um SJ; Park SN; Kim SJ; Namkoong SE
Gynecol Oncol; 1998 Apr; 69(1):47-55. PubMed ID: 9570998
[TBL] [Abstract][Full Text] [Related]
46. Smoking impairs human papillomavirus (HPV) type 16 and 18 capsids antibody response following natural HPV infection.
Simen-Kapeu A; Kataja V; Yliskoski M; Syrjänen K; Dillner J; Koskela P; Paavonen J; Lehtinen M
Scand J Infect Dis; 2008; 40(9):745-51. PubMed ID: 19086247
[TBL] [Abstract][Full Text] [Related]
47. Serum antibody against unfused recombinant E7 protein of human papillomavirus type 16 in cervical cancer patients.
Fujii T; Matsushima Y; Yajima M; Sugimura T; Terada M
Jpn J Cancer Res; 1995 Jan; 86(1):28-34. PubMed ID: 7737906
[TBL] [Abstract][Full Text] [Related]
48. Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.
Phaëton R; Gutierrez J; Jiang Z; Karabakhtsian RG; Albanese J; Sunkara J; Fisher DR; Goldberg GL; Dadachova E
Immunotherapy; 2015; 7(6):631-40. PubMed ID: 26098137
[TBL] [Abstract][Full Text] [Related]
49. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses.
Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB
Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245
[TBL] [Abstract][Full Text] [Related]
50. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.
Bubenik J
Curr Cancer Drug Targets; 2008 May; 8(3):180-6. PubMed ID: 18473731
[TBL] [Abstract][Full Text] [Related]
51. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses.
David MP; Van Herck K; Hardt K; Tibaldi F; Dubin G; Descamps D; Van Damme P
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S1-6. PubMed ID: 19217149
[TBL] [Abstract][Full Text] [Related]
52. Cervical cancer screening: which HPV test should be used--L1 or E6/E7?
Tjalma WA; Depuydt CE
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):45-6. PubMed ID: 23932300
[TBL] [Abstract][Full Text] [Related]
53. E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients.
Dang C; Koehler A; Forschner T; Sehr P; Michael K; Pawlita M; Stockfleth E; Nindl I
Br J Dermatol; 2006 Jul; 155(1):129-36. PubMed ID: 16792764
[TBL] [Abstract][Full Text] [Related]
54. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
55. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity.
Schädlich L; Senger T; Kirschning CJ; Müller M; Gissmann L
Vaccine; 2009 Mar; 27(10):1511-22. PubMed ID: 19174177
[TBL] [Abstract][Full Text] [Related]
56. Detection of anti-HPV11-L1 antibodies in immune sera from patients suffering from recurrent respiratory papillomatosis using ELISA.
Durzyńska J; Błazejewska P; Szydłowski J; Goździcka-Józefiak A
Viral Immunol; 2010 Aug; 23(4):415-23. PubMed ID: 20712486
[TBL] [Abstract][Full Text] [Related]
57. Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias.
Sasagawa T; Inoue M; Tanizawa O; Yutsudo M; Hakura A
Jpn J Cancer Res; 1992 Jul; 83(7):705-13. PubMed ID: 1325428
[TBL] [Abstract][Full Text] [Related]
58. Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer.
Skiba D; Mehlhorn G; Fasching PA; Beckmann MW; Ackermann S
Anticancer Res; 2006; 26(6C):4921-6. PubMed ID: 17214363
[TBL] [Abstract][Full Text] [Related]
59. Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies.
Hu R; Dong Z; Zhang K; Pan G; Li C; Cui H
Viruses; 2020 Mar; 12(3):. PubMed ID: 32204370
[TBL] [Abstract][Full Text] [Related]
60. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection.
Farhat S; Nakagawa M; Moscicki AB
Int J Gynecol Cancer; 2009 May; 19(4):508-12. PubMed ID: 19509544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
